Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $47.7 million.

  • Haemonetics' Shares Outstanding (Diluted Average) fell 680.38% to $47.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $47.7 million, marking a year-over-year decrease of 680.38%. This contributed to the annual value of $50.7 million for FY2025, which is 129.77% down from last year.
  • Latest data reveals that Haemonetics reported Shares Outstanding (Diluted Average) of $47.7 million as of Q4 2025, which was down 680.38% from $48.0 million recorded in Q3 2025.
  • Haemonetics' Shares Outstanding (Diluted Average)'s 5-year high stood at $51.7 million during Q3 2022, with a 5-year trough of $47.7 million in Q4 2025.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $50.9 million, with a median of $51.4 million in 2022.
  • In the last 5 years, Haemonetics' Shares Outstanding (Diluted Average) soared by 146.06% in 2022 and then crashed by 680.38% in 2025.
  • Quarter analysis of 5 years shows Haemonetics' Shares Outstanding (Diluted Average) stood at $51.5 million in 2021, then increased by 0.06% to $51.5 million in 2022, then fell by 0.08% to $51.4 million in 2023, then fell by 0.58% to $51.1 million in 2024, then decreased by 6.8% to $47.7 million in 2025.
  • Its last three reported values are $47.7 million in Q4 2025, $48.0 million for Q3 2025, and $48.4 million during Q2 2025.